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SUMMARY
Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-
diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated 
liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the 
near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence 
of treatment-related ≥Grade 3 non-haematological toxicity (80% vs 51%, P = 0.020). Median 
overall survival was 5.6 years and negatively impacted by the presence of International Staging 
System stage III disease, underscoring the need for novel treatment strategies for this group of 
patients.
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INTRODUCTION
A phase I study of pegylated liposomal doxorubicin (PegLD) and bortezomib in 
haematological malignancies identified the maximum tolerated dose of the regimen and 
demonstrated notable activity in patients with multiple myeloma (Orlowski et al, 2005). A 
subsequent phase III study comparing single agent bortezomib to PegLD/bortezomib in 
bortezomib-naïve patients with relapsed multiple myeloma yielded a median time to 
progression (TTP) of 6.5 and 9.3 months (P = 0.000004), respectively (Orlowski et al, 
2007). Given the compelling pre-clinical and phase I clinical data supporting the 
combination of PegLD/bortezomib, the Cancer And Leukemia Group B (CALGB, now part 
of the Alliance for Clinical Trials in Oncology) sought to evaluate the efficacy and safety of 
bortezomib and PegLD in patients with newly -diagnosed multiple myeloma in a single arm 
phase II multicentre study. We have previously presented the short-term safety and efficacy 
data of this combination (Orlowski et al, 2006). With long-term follow-up, we performed a 
post hoc analysis of clinical variables that impact outcomes of patients prospectively treated 
with an upfront, bortezomib-based regimen. An equal distribution of younger and older 
patients on this study provided an opportunity to evaluate the impact of age on survival and 
treatment tolerability. Here we report long-term results of the only study of the PegLD and 
bortezomib doublet in the frontline setting.
METHODS
Please refer to supplemental data for details regarding patient eligibility, study design and 
treatment, and assessment of efficacy and safety (Data S1).
Statistical Analysis
With a planned enrolment of 50 evaluable patients, this single stage study had 0.9 power and 
a type I error rate of 0.06 to test whether the regimen could induce a near-complete 
response / complete response (nCR/CR) rate greater than 0.10 under the null hypothesis that 
the nCR/CR rate with PegLD and bortezomib is ≤10% versus the alternate hypothesis of 
≥25%.
Best achieved response rates were assessed as the proportion of patients achieving each type 
of confirmed response, and exact 95% confidence intervals (CIs) for the true rate were 
calculated, assuming a binomial distribution for each response category. Survival functions 
for overall survival (OS), progression-free survival (PFS), event-free survival (EFS), 
duration of response (DOR) and time to response (TTR) were estimated using the Kaplan–
Meier method (Kaplan & Meier, 1958). The differences between survival distributions with 
respect to age, dichotomized at 65 years, and other baseline clinical characteristics were 
evaluated using the log-rank test. Hazard ratios and their 95% CIs were estimated using a 
Cox regression model (Cox, 1972). Differences in baseline clinical characteristics between 
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those responding to therapy and those with unresponsive disease were evaluated using the 
score statistic from logistic regression models. Cumulative incidence with competing risks 
was used to assess potential differences between age groups when factoring in the following 
competing risks: death, progression, receipt of non-protocol therapy and stem cell transplant 
(Fine and Gray, 1999).
Data collection and statistical analyses were conducted by the Alliance Statistics and Data 
Center (Durham, NC). Data quality was ensured by review of data by the Alliance Statistics 
and Data Center and by the study chairperson following Alliance policies. Statistical 
analyses were performed by CALGB (Alliance) statisticians using SAS 9.2 (SAS Institute, 
Inc., Cary, NC) and R package version 2.15.1 (http://www.R-project.org/) and were based on 
the study database frozen on 7 April 2014. The cmprsk extension package (version 2.2-2) 
was used for the purpose of estimation and inference for the cumulative incidence curves 
(Gray, 2011). P values ≤0.05 were considered statistically significant
RESULTS
Efficacy
,A total of 63 patients with newly diagnosed, symptomatic multiple myeloma enrolled on the 
study between 15 June 2004 and 25 October 2005. Information regarding patient disposition, 
therapy received and baseline demographics are provided as supplementary data (Data S1, 
Table S1).
Sixty-one patients were evaluable for response. The overall response rate (ORR) was 57% 
(95% CI 44 – 70%) and nCR/CR rate 7% (95% CI 2 – 16%) (Table I). The median TTR was 
1.2 months (95% CI 1.1–1.5 months) and median DOR 17.5 months (95% CI 9.7 – 25.7 
months).
Median follow-up was 6.6 years; to date, 47 patients have had disease progression and 39 
have died. Data on PFS and EFS are provided as supplementary data (Data S1, Figure S1). 
The median OS was 5.6 years (95% CI 4.0 – 6.8 years) and was not significantly different 
when stratified by gender, race, Durie-Salmon stage or renal function. The median OS was 
6.8 years for those aged <65 years (95% CI 4.2 – 8.3 years) and 4.0 years for those ≥65 
years of age (95% CI 3.0 – 6.2 years, P = 0.058) (Figure 1A). Those with International 
Staging System (ISS) III disease had a median OS of 4.0 years (95% CI 2.6 – 5.6 years) 
compared to 6.4 years for stage I or II disease (95% CI 4.6 – 8.3 years, P = 0.022)(Figure 
1B). Among the variables age, gender, ISS stage, renal function, platelets and haemoglobin, 
only ISS stage was statistically significant, where those with ISS stage III disease had a 
hazard of death that was 2.13 times greater than those with ISS stage I and II disease 
(p=0.026) (Table S2). OS was longer for patients achieving ≥very good partial response 
(VGPR), with a median OS of 8.3 years (95% CI 6.2 – 8.3 years) compared with 4.2 years 
(95% CI 3.2 – 6.4 years) for those with < VGPR (Figure 1C, P = 0.048).
Safety
Sixty-one patients were evaluable for safety. Therapy-related ≥Grade 3 haematological and 
non-haematological adverse events were seen in 44% and 66% of patients, respectively 
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(Table S3). Grade 3 and higher treatment-related non-haematological adverse events were 
seen more often in older patients, occurring in 80% compared with 51% for those aged <65 
years (P = 0.020). Thirty per cent of those aged ≥65 years had to stop protocol treatment due 
to adverse events, in contrast to 19% of those <65 years old. Additional data on commonly 
experienced adverse events, treatment delays, dose reductions and stem cell mobilization 
and engraftment are provided as supplementary data (Data S1, Table S4).
DISCUSSION
The nCR/CR rate with PegLD/bortezomib was lower than expected given the fact that 
nCR/CR rates of 13% – 36% were seen in phase I and III studies of the combination in 
patients with relapsed or refractory multiple myeloma (Orlowski et al, 2005, Orlowski et al, 
2007). However, in line with our results, the addition of PegLD to bortezomib did not 
improve the nCR/CR rate compared with bortezomib for relapsed multiple myeloma patients 
treated on a phase III study (13% vs 10%) (Orlowski et al, 2007), and the nCR/CR rate of 
bortezomib monotherapy in the frontline setting was only 9% (Richardson et al, 2009). In 
contrast, a phase II study evaluating PegLD/bortezomib in combination with dexamethasone 
demonstrated an ORR of 85.0% and nCR/CR rate of 37.5% after 6 cycles (Jakubowiak et al, 
2009), highlighting the efficacy of dexamethasone in newly diagnosed patients. Nonetheless, 
the ORR in our study was notable for a corticosteroid-free regimen, recognizing that such 
regimens have not been rigorously evaluated as frontline therapy. As such, PegLD/
bortezomib could represent a potential therapeutic option for newly diagnosed patients who 
have more significant contraindications to the use of corticosteroid-containing therapy
Patients with ISS stage III disease had a decreased median OS compared to those with ISS 
stage I and II disease, reaffirming the prognostic value of the ISS for patients treated with 
this regimen. Our results are consistent with previous retrospective analyses demonstrating 
the prognostic relevance of the ISS for those treated with novel therapies (Kastritis et al, 
2009; Srivastava et al, 2013). Nonetheless, the value of the ISS will require on-going re-
validation with the emergence of newer combinations.
Age has been shown to be a predictor of survival in multiple myeloma, but much of these 
data were derived from patients treated prior to the availability of bortezomib (Avet-Loiseau 
et al, 2013, Turesson et al, 2010). In our study, there was a strong trend toward inferior 
outcomes for those aged ≥65 years. Although we were not able to evaluate differences in the 
incidence of high-risk cytogenetic abnormalities in older and younger patients treated on this 
study given the small number of patients with cytogenetically-confirmed high-risk disease, 
the proportion of patients with ISS stage III disease was evenly distributed. A potentially 
more compelling reason for the disparity in outcomes is that older patients do not tolerate 
therapy as well, leading to more dose reductions and delays and earlier discontinuation of 
treatment. Notably, patients aged ≥65 years on our study experienced more treatment-related 
≥Grade 3 non-haematological toxicity, and 30% developed Grade 3 fatigue, which may have 
led to more dose modifications and treatment discontinuations.
In conclusion, PegLD/bortezomib therapy in newly diagnosed multiple myeloma did not 
meet the nCR/CR rate specified in the protocol and was associated with increased adverse 
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events in older patients. Overall survival was reflective of the therapeutic advances made in 
multiple myeloma over the last 10 years but negatively impacted by the presence of ISS 
stage III disease. Last, our results reveal potential differences in treatment tolerability and 
overall survival for older patients treated with PegLD/bortezomib. A better understanding of 
the impact of age on treatment tolerability and survival with novel induction regimens will 
be critical if we are to further improve outcomes for this patient population.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Overall survival by (A) age <65years vs. ≥65 years, (B) International Staging System score 
and (C) response to therapy (<VGPR vs. ≥VGPR, for patients treated with pegylated 
liposomal doxorubicin and bortezomib. VGPR, very good partial response; PR, partial 
response.
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Table I
Response data with pegylated liposomal doxorubicin and bortezomib
Best Response N % 95% CI
Modified EBMT Criteria
Overall Response 35 57 44 – 70
 Complete Response* 3 5 1 – 14
 Near Complete Response* 1 2 0 – 9
 Partial Response 31 51 38 – 64
Near Complete Response + Complete Response 4 7 2 – 16
Minimal Response 6 10 4 – 20
Stable Disease 15 25 15 – 37
Progressive Disease 1 2 0 – 9
Not Evaluable 4 7 2 – 16
IMWG Criteria
Overall Response 35 57 44 – 70
 Complete Response 3 5 1 – 14
 Very Good Partial Response 13 21 12 – 34
 Partial Response 19 31 20 – 44
Median Time to Response, months (95% CI) 1.2 (1.1 – 1.5)
*
All near complete and complete responses were seen in the first 50 evaluable patients.
Abbreviations: EBMT=European Group for Blood and Marrow Transplant (Blade et al, 1998); IMWG=International Myeloma Working Group 
(Rajkumar et al, 2011)
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